Odonate Therapeutics (NASDAQ:ODT) issued its earnings results on Thursday. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.98) by ($0.11), MarketWatch Earnings reports.
ODT opened at $36.37 on Friday. The business’s 50 day moving average is $39.43 and its 200-day moving average is $31.76. Odonate Therapeutics has a twelve month low of $18.07 and a twelve month high of $46.50.
A number of equities research analysts have recently weighed in on the company. ValuEngine raised Odonate Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 28th. BidaskClub cut Odonate Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. Finally, Zacks Investment Research cut Odonate Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 1st.
About Odonate Therapeutics
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Featured Article: What is the price-sales ratio?
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.